A Randomized, Eploratory, Open Clinical Trial to Compare the Efficacy and Safety of Anlotinib Plus Irinotecan Versus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Trial Profile

A Randomized, Eploratory, Open Clinical Trial to Compare the Efficacy and Safety of Anlotinib Plus Irinotecan Versus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Anlotinib (Primary) ; Irinotecan
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2018 New trial record
    • 03 Jan 2018 Planned number of patients changed from 20 to 120.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top